These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

813 related articles for article (PubMed ID: 22536382)

  • 1. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus.
    Tseng CT; Sbrana E; Iwata-Yoshikawa N; Newman PC; Garron T; Atmar RL; Peters CJ; Couch RB
    PLoS One; 2012; 7(4):e35421. PubMed ID: 22536382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine.
    Iwata-Yoshikawa N; Uda A; Suzuki T; Tsunetsugu-Yokota Y; Sato Y; Morikawa S; Tashiro M; Sata T; Hasegawa H; Nagata N
    J Virol; 2014 Aug; 88(15):8597-614. PubMed ID: 24850731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology.
    Honda-Okubo Y; Barnard D; Ong CH; Peng BH; Tseng CT; Petrovsky N
    J Virol; 2015 Mar; 89(6):2995-3007. PubMed ID: 25520500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gold nanoparticle-adjuvanted S protein induces a strong antigen-specific IgG response against severe acute respiratory syndrome-related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs.
    Sekimukai H; Iwata-Yoshikawa N; Fukushi S; Tani H; Kataoka M; Suzuki T; Hasegawa H; Niikura K; Arai K; Nagata N
    Microbiol Immunol; 2020 Jan; 64(1):33-51. PubMed ID: 31692019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model.
    Du L; Zhao G; He Y; Guo Y; Zheng BJ; Jiang S; Zhou Y
    Vaccine; 2007 Apr; 25(15):2832-8. PubMed ID: 17092615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge.
    Bolles M; Deming D; Long K; Agnihothram S; Whitmore A; Ferris M; Funkhouser W; Gralinski L; Totura A; Heise M; Baric RS
    J Virol; 2011 Dec; 85(23):12201-15. PubMed ID: 21937658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses.
    Spruth M; Kistner O; Savidis-Dacho H; Hitter E; Crowe B; Gerencer M; Brühl P; Grillberger L; Reiter M; Tauer C; Mundt W; Barrett PN
    Vaccine; 2006 Jan; 24(5):652-61. PubMed ID: 16214268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formalin-treated UV-inactivated SARS coronavirus vaccine retains its immunogenicity and promotes Th2-type immune responses.
    Tsunetsugu-Yokota Y; Ato M; Takahashi Y; Hashimoto S; Kaji T; Kuraoka M; Yamamoto K; Mitsuki YY; Yamamoto T; Oshima M; Ohnishi K; Takemori T
    Jpn J Infect Dis; 2007 May; 60(2-3):106-12. PubMed ID: 17515642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus.
    Cavanagh D
    Avian Pathol; 2003 Dec; 32(6):567-82. PubMed ID: 14676007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein.
    Fett C; DeDiego ML; Regla-Nava JA; Enjuanes L; Perlman S
    J Virol; 2013 Jun; 87(12):6551-9. PubMed ID: 23576515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV.
    Yasui F; Kai C; Kitabatake M; Inoue S; Yoneda M; Yokochi S; Kase R; Sekiguchi S; Morita K; Hishima T; Suzuki H; Karamatsu K; Yasutomi Y; Shida H; Kidokoro M; Mizuno K; Matsushima K; Kohara M
    J Immunol; 2008 Nov; 181(9):6337-48. PubMed ID: 18941225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.
    Liu YV; Massare MJ; Barnard DL; Kort T; Nathan M; Wang L; Smith G
    Vaccine; 2011 Sep; 29(38):6606-13. PubMed ID: 21762752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and protective efficacy in mice and hamsters of a β-propiolactone inactivated whole virus SARS-CoV vaccine.
    Roberts A; Lamirande EW; Vogel L; Baras B; Goossens G; Knott I; Chen J; Ward JM; Vassilev V; Subbarao K
    Viral Immunol; 2010 Oct; 23(5):509-19. PubMed ID: 20883165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus.
    Agrawal AS; Tao X; Algaissi A; Garron T; Narayanan K; Peng BH; Couch RB; Tseng CT
    Hum Vaccin Immunother; 2016 Sep; 12(9):2351-6. PubMed ID: 27269431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.
    See RH; Zakhartchouk AN; Petric M; Lawrence DJ; Mok CPY; Hogan RJ; Rowe T; Zitzow LA; Karunakaran KP; Hitt MM; Graham FL; Prevec L; Mahony JB; Sharon C; Auperin TC; Rini JM; Tingle AJ; Scheifele DW; Skowronski DM; Patrick DM; Voss TG; Babiuk LA; Gauldie J; Roper RL; Brunham RC; Finlay BB
    J Gen Virol; 2006 Mar; 87(Pt 3):641-650. PubMed ID: 16476986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epitope mapping and biological function analysis of antibodies produced by immunization of mice with an inactivated Chinese isolate of severe acute respiratory syndrome-associated coronavirus (SARS-CoV).
    Chou TH; Wang S; Sakhatskyy PV; Mboudjeka I; Lawrence JM; Huang S; Coley S; Yang B; Li J; Zhu Q; Lu S
    Virology; 2005 Mar; 334(1):134-43. PubMed ID: 15749129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine.
    Qin E; Shi H; Tang L; Wang C; Chang G; Ding Z; Zhao K; Wang J; Chen Z; Yu M; Si B; Liu J; Wu D; Cheng X; Yang B; Peng W; Meng Q; Liu B; Han W; Yin X; Duan H; Zhan D; Tian L; Li S; Wu J; Tan G; Li Y; Li Y; Liu Y; Liu H; Lv F; Zhang Y; Kong X; Fan B; Jiang T; Xu S; Wang X; Li C; Wu X; Deng Y; Zhao M; Zhu Q
    Vaccine; 2006 Feb; 24(7):1028-34. PubMed ID: 16388880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity.
    Buchholz UJ; Bukreyev A; Yang L; Lamirande EW; Murphy BR; Subbarao K; Collins PL
    Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9804-9. PubMed ID: 15210961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants.
    Deming D; Sheahan T; Heise M; Yount B; Davis N; Sims A; Suthar M; Harkema J; Whitmore A; Pickles R; West A; Donaldson E; Curtis K; Johnston R; Baric R
    PLoS Med; 2006 Dec; 3(12):e525. PubMed ID: 17194199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines.
    See RH; Petric M; Lawrence DJ; Mok CPY; Rowe T; Zitzow LA; Karunakaran KP; Voss TG; Brunham RC; Gauldie J; Finlay BB; Roper RL
    J Gen Virol; 2008 Sep; 89(Pt 9):2136-2146. PubMed ID: 18753223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.